{"doi":"10.1210/clinem/dgad027","title":"Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study","abstract":"CONTEXT: Nicotinamide adenine dinucleotide (NAD) levels decline with aging and age-related decline in NAD has been postulated to contribute to age-related diseases. OBJECTIVE: We evaluated the safety and physiologic effects of NAD augmentation by administering its precursor, β-nicotinamide mononucleotide (MIB-626, Metro International Biotech, Worcester, MA), in adults at risk for age-related conditions. METHODS: Thirty overweight or obese adults, ≥ 45 years, were randomized in a 2:1 ratio to 2 MIB-626 tablets each containing 500 mg of microcrystalline β-nicotinamide mononucleotide or placebo twice daily for 28 days. Study outcomes included safety; NAD and its metabolome; body weight; liver, muscle, and intra-abdominal fat; insulin sensitivity; blood pressure; lipids; physical performance, and muscle bioenergetics. RESULTS: Adverse events were similar between groups. MIB-626 treatment substantially increased circulating concentrations of NAD and its metabolites. Body weight (difference -1.9 [-3.3, -0.5] kg, P = .008); diastolic blood pressure (difference -7.01 [-13.44, -0.59] mmHg, P = .034); total cholesterol (difference -26.89 [-44.34, -9.44] mg/dL, P = .004), low-density lipoprotein (LDL) cholesterol (-18.73 [-31.85, -5.60] mg/dL, P = .007), and nonhigh-density lipoprotein cholesterol decreased significantly more in the MIB-626 group than placebo. Changes in muscle strength, muscle fatigability, aerobic capacity, and stair-climbing power did not differ significantly between groups. Insulin sensitivity and hepatic and intra-abdominal fat did not change in either group. CONCLUSIONS: MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.","journal":"The Journal of Clinical Endocrinology & Metabolism","year":2023,"id":320525,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9611,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":342254,"name":"Rodrigo J. Valderrábano","orcid":"0000-0002-4910-3997","position":1,"is_corresponding":false},{"id":1031228,"name":"Benjamin Wipper","orcid":"0000-0002-3143-5627","position":2,"is_corresponding":false},{"id":341309,"name":"Ariela R. Orkaby","orcid":"0000-0002-4297-6306","position":3,"is_corresponding":false},{"id":434462,"name":"Kieran F. Reid","orcid":"0000-0001-9652-5319","position":4,"is_corresponding":false},{"id":242030,"name":"Thomas W. Storer","orcid":"0000-0002-5974-9791","position":5,"is_corresponding":false},{"id":274934,"name":"Alexander Lin","orcid":"0000-0001-8236-880X","position":6,"is_corresponding":false},{"id":800469,"name":"Sai Merugumala","orcid":null,"position":7,"is_corresponding":false},{"id":956593,"name":"Lauren Wilson","orcid":"0009-0004-0692-4201","position":8,"is_corresponding":false},{"id":243936,"name":"Nancy K. Latham","orcid":null,"position":9,"is_corresponding":false},{"id":1031695,"name":"Catherine Ghattas‐Puylara","orcid":null,"position":10,"is_corresponding":false},{"id":1001070,"name":"Noelle Ozimek","orcid":"0009-0003-5468-7469","position":11,"is_corresponding":false},{"id":673717,"name":"Ming Cheng","orcid":"0009-0006-8475-2331","position":12,"is_corresponding":false},{"id":1031696,"name":"Avantika Bhargava","orcid":null,"position":13,"is_corresponding":false},{"id":1031697,"name":"Yusnie Memish‐Beleva","orcid":null,"position":14,"is_corresponding":false},{"id":324999,"name":"Brian Lawney","orcid":null,"position":15,"is_corresponding":false},{"id":1031698,"name":"Siva Lavu","orcid":null,"position":16,"is_corresponding":false},{"id":1031699,"name":"Pamela M Swain","orcid":null,"position":17,"is_corresponding":false},{"id":328045,"name":"Rajendra S. Apte","orcid":"0000-0003-2281-2336","position":18,"is_corresponding":false},{"id":106661,"name":"David Sinclair","orcid":"0000-0002-9936-436X","position":19,"is_corresponding":false},{"id":730085,"name":"David H. Livingston","orcid":"0000-0003-0427-0393","position":20,"is_corresponding":false},{"id":109414,"name":"Shalender Bhasin","orcid":"0000-0002-3982-6200","position":21,"is_corresponding":false},{"id":109418,"name":"Karol M. Pencina","orcid":"0000-0003-1824-7047","position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-19T01:07:22.377587Z","pmid":"36740954","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}